Literature DB >> 20334568

Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects.

Lucinda Aguirre-Cruz1, Klintsy J Torres, Helgi Jung-Cook, Carlos Fortuny, Eder Sánchez, Antonio Soda-Mehry, Julio Sotelo, Gustavo Reyes-Terán.   

Abstract

Hydroxychloroquine (HCQ) anti-HIV activity is well documented. To evaluate its distribution in lymphoid tissues, which are considered sanctuaries of HIV reservoirs and targets of early massive depletion of CD4(+) T cells, we assessed HCQ concentrations in adenoid tissue and plasma of HIV-infected subjects. A daily oral dose of 400 or 800 mg of HCQ was administered to eight HIV-infected subjects for 8 days. HCQ concentrations were measured in plasma and adenoid tissue by high-performance liquid chromatography. Mean concentrations of HCQ in adenoid tissue of subjects treated with 400 and 800 mg were 87,210 +/- 17,817 and 167,472 +/- 93,793 ng/g, respectively. In plasma, these values corresponded to 329 +/- 133 and 278 +/- 68 ng/g, respectively. HCQ concentrations were significantly higher in adenoid tissue than in plasma in both groups. The potential use of HCQ as adjuvant in the therapy of HIV deserves to be explored, as the drug accumulates in relevant tissues for HIV replication and immunopathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334568     DOI: 10.1089/aid.2009.0129

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection.

Authors:  Iliana González-Hernández; Lucinda Aguirre-Cruz; Julio Sotelo; Raquel López-Arellano; Adriana Morales-Hipólito; Helgi Jung-Cook
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

2.  Multi-Compartment Lymph-Node-on-a-Chip Enables Measurement of Immune Cell Motility in Response to Drugs.

Authors:  Nicholas Hallfors; Aya Shanti; Jiranuwat Sapudom; Jeremy Teo; Georg Petroianu; SungMun Lee; Lourdes Planelles; Cesare Stefanini
Journal:  Bioengineering (Basel)       Date:  2021-01-31

3.  Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC.

Authors:  Johanna M Gostner; Sebastian Schröcksnadel; Kathrin Becker; Marcel Jenny; Harald Schennach; Florian Uberall; Dietmar Fuchs
Journal:  FEBS Open Bio       Date:  2012-08-17       Impact factor: 2.693

Review 4.  Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation.

Authors:  Moritz Ries; Kathrin Pritschet; Barbara Schmidt
Journal:  Clin Dev Immunol       Date:  2011-11-29

Review 5.  Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.

Authors:  Andrea Savarino; Iart Luca Shytaj
Journal:  Retrovirology       Date:  2015-06-18       Impact factor: 4.602

6.  Influence of quinacrine and chloroquine on the in vitro 3'-azido-3'-deoxythymidine antiretroviral effect.

Authors:  Klintsy J Torres; Gustavo Reyes-Terán; Julio Sotelo; Helgi Jung-Cook; Lucinda Aguirre-Cruz
Journal:  AIDS Res Ther       Date:  2015-03-19       Impact factor: 2.250

7.  Use of chloroquine in viral diseases.

Authors:  Andrea Savarino
Journal:  Lancet Infect Dis       Date:  2011-05-05       Impact factor: 25.071

8.  Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.

Authors:  Immacolata Faraone; Fabiana Labanca; Maria Ponticelli; Nunziatina De Tommasi; Luigi Milella
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

9.  Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Zhe Chen; Aihua Liu; Yongjing Cheng; Xutao Wang; Xiaomao Xu; Jia Huang; Yuqing Ma; Ming Gao; Cibo Huang
Journal:  BMC Infect Dis       Date:  2021-08-12       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.